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BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with
the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients.
MATERIALS AND METHODS: Patients were randomly assigned to D 30mgm
 2 as intravenous infusion (i.v.) and EPI 30mgm
 2 i.v. every
week (D/EPI arm), or D 70mgm
 2 i.v. every 3 weeks and oral P 5mg twice daily (D/P arm). Chemotherapy was administered until
disease progression or unacceptable toxicity.
RESULTS: A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The
median progression-free survival (PFS) was 11.1 months (95% CI 9.2–12.6 months) in the D/EPI arm and 7.7 months (95% CI
5.7–9.4 months) in the D/P arm (P¼0.0002). The median survival was 27.3 months (95% CI 22.1–30.8 months) in the D/EPI arm
and 19.8 months (95% CI 14.4–24.8 months) in the D/P arm (P¼0.003). Both regimens were generally well tolerated.
CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to
superior PFS than the treatment with 3-weekly D and oral P.
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The results of two large randomised trials have provided
substantial support in favour of the role of chemotherapy in the
treatment of castrate-resistant prostate cancer (CRPC) by demon-
strating that docetaxel (D) and prednisone (P) improve survival in
comparison with older regimens, and significantly improve the
quality of life (Petrylak et al, 2004; Tannock et al, 2004).
Although D/P combination has become the first-line standard of
care for advanced CRPC, PSA responses rarely exceed 50% and
median survival is less than 20 months. The use of chemotherapy
in CRPC therefore remains a subject of active clinical investigation,
and the mild toxicity of D makes it an attractive treatment option
for the development of combination regimens.
Docetaxel is usually administered at a dose of 70–75mgm
 2
every 3 weeks or on a weekly basis at a dose of 30–36mgm
 2.
However, according to the TAX327 trial, weekly D was not equally
effective when compared with D given at 3-week intervals in
the treatment of advanced CRPC, and furthermore, weekly D was
not superior to mitoxantrone (Tannock et al, 2004). The toxicity
profiles of the weekly and 3-weekly treatment are distinctly
different (Engels and Verweij, 2005). The acute toxicity of weekly D
(particularly myelosuppression) is mild and never dose limiting,
which is why this schedule is proposed above all for patients with
poor performance status (PS), decreased haematological reserve or
multiple co-morbidities, and for elderly patients (Beer et al, 2001;
Petrioli et al, 2003).
Among other chemotherapeutic agents, doxorubicin has shown
some activity in CRPC, and we have previously described the
satisfactory effectiveness of the doxorubicin analogue epirubicin
(EPI) that, at equipotent doses, is associated with quantitatively
less severe toxicities than its parent compound (Francini et al,
1993; Brausi et al, 1995; Petrioli et al, 2002). More recently, we
reported, in a phase II study, the activity (68.4% PSA response and
72.7% palliative response) and tolerability of the combination of
weekly D and weekly EPI in advanced CRPC patients (Petrioli et al,
2007). The promising results observed during the course of that
experience provided the rationale to compare the activity of the
combination D/EPI with the conventional treatment D/P in terms
of progression-free survival (PFS) in advanced CRPC patients.
PATIENTS AND METHODS
Eligibility criteria
The study involved patients with histologically confirmed,
measurable, or evaluable advanced prostatic adenocarcinoma
progressing during hormonal therapy. They were admitted to the
Received 22 October 2010; revised 3 December 2010; accepted 29
December 2010; published online 1 February 2011
*Correspondence: Dr R Petrioli; E-mail: r.petrioli@ao-siena.toscana.it
British Journal of Cancer (2011) 104, 613–619
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
schemotherapy protocol, provided that they met at least one of the
following criteria: a positive bone scan and a X25% increase in
PSA (PSA higher than 5ngml
 1) in comparison with baseline on
two successive occasions separated by at least 2 weeks for patients
without measurable disease; new metastatic lesions revealed by a
bone scan; and a 25% increase in a bidimensionally measurable
tumour mass. The patients treated with LH-RH agonists had
to continue their primary androgen ablation therapy, and were
required to have serum testosterone levels of o50ngml
 1 before
study entry. Anti-androgen agents had to be stopped 4–6 weeks
before the use of chemotherapy to allow the withdrawal to become
effective. All of the patients had to have an Eastern Coopera-
tive Oncology Group PS of p2 and adequate haematological
(leukocytes X3000mm
 3; haemoglobin X10gdl
 1; and platelets
X100000mm
 3), renal (serum creatinine p2.0mgdl
 1), and
hepatic functions (serum bilirubin p2.0mgdl
 1). The exclusion
criteria were previous chemotherapy, congestive heart failure, a
recent myocardial infarction, or any other previous malignant
disease except basal cell carcinoma of the skin. All of the patients
gave their informed consent, and the protocol was approved by the
Ethics Review Board of Siena University.
Treatment plan
In D/EPI arm, the treatment consisted of D 30mgm
 2 as a 30-min
intravenous infusion (i.v.) and a bolus of EPI 30mgm
 2 diluted
with 100ml of saline solution, based on a schedule of 6 consecutive
weekly administrations, followed by a 2-week rest interval. In D/P
arm, treatment consisted of D 70mgm
 2 intravenously every 3
weeks and oral P 5mg twice daily. Given that elderly patients,
patients with co-morbidities, and/or patients with poor PS are not
expected to tolerate the full-dose 3-weekly regimen (Engels and
Verweij, 2005), a slightly lower dose of D (70mgm
 2) instead of
the conventional 75mgm
 2 was chosen for the current trial.
Cycles were administered, if serum WBC levels were 43000mm
 3,
granulocytes 41500mm
 3, and platelets 4100000mm
 3.P r e -
medication consisted of dexamethasone 8mg orally 12h before, at
the time of, and 12h after D administration. Ondansetron 8mg was
administered at the beginning of each treatment cycle as antiemetic
medication. The patients continued to take analgesic medication
at doses adjusted to provide optimal pain control. All patients with
bone metastases received bisphosphonates (zoledronic acid 4mg i.v.
every 4 weeks).
The chemotherapy was administered until disease progression
or unacceptable toxicity, and for a maximum of 30 weekly cycles
(EPI for a maximum of 24 cycles) in the D/EPI arm and for a
maximum of 10 three-weekly cycles in the D/P arm. The maximum
planned cumulative dose of EPI was 720mgm
 2.
Response assessments
Serum PSA was measured every 3 weeks, and PSA criteria for
response and progression were based on the PSA Working Group
(PWG) consensus criteria (Bubley et al, 1999): a PSA response was
defined as a reduction from baseline of at least 50% for at least 3
weeks (instead of 4 weeks in the PWG criteria), whereas PSA
progression was defined as an increase from nadir of at least 25%
in patients without biochemical response or X50% PSA increase
in patients with previous biochemical response. Blood and platelet
counts, and a comprehensive screening profile were performed at
baseline and every 3 weeks. The patients in the D/EPI arm
underwent a weekly complete blood cell count before chemother-
apy. The baseline imaging studies included abdominal and pelvic
CT or magnetic resonance imaging, a bone scan, and chest
radiography. All measurable disease (not bone lesions) was
re-evaluated at 8-week intervals using the Response Evaluation
Criteria in Solid Tumors (Therasse et al, 2000), and a radionuclide
bone scan was repeated every 6 months.
All of the patients underwent a baseline ECG, and their left
ventricular ejection fraction (LVEF) was measured by means of a
multiple gated acquisition scan or echocardiography at baseline
and every 12 weeks; further cardiac examinations were performed
as indicated. A major decrease in LVEF was defined as an absolute
decrease to at least 15% below the lower normal limit.
A radionuclide bone scan was performed at baseline and
repeated every 6 months. Bone markers were measured at baseline
and after 3 months of treatment: the bone resorption marker
s-CTX (serum C-telopeptide of collagen type I) was evaluated by
an ELISA method (Serum Cross Laps ELISA, Nordic Bioscience
Diagnostics, Herlev, Denmark) and the bone formation marker
B-ALP (bone-alkaline phosphatase) by a radioimmunometric
method (B-ALP Tandem-R Ostase, Hybritech, Merceville, NJ,
USA). Bone disease progression was defined as the appearance of
any new bone lesion or the progression of existing bone metastases.
Pain symptomatology was measured at baseline and then
every 6 weeks by the McGill Melzack Pain Questionnaire, and
pain response was defined as a 2-point reduction in the 6-point
present pain intensity scale (or the complete disappearance of
pain, if the initial score was 1þ) (Melzack, 1975). These results
had to be maintained at two consecutive evaluations made at least
3 weeks apart and without any increase in analgesic consumption.
The patients were asked to classify the average pain level during
the previous 24h: we used a translated form of the McGill Melzack
Questionnaire to which the ‘reconstruction-based methodology’
has been applied (De Benedittis et al, 1988). Analgesic consump-
tion was based on the average daily quantities taken by the patient
during the previous week and assigned oral morphine equivalents
before analysis (McCormack et al, 1992).
To evaluate the impact of treatment on quality of life, all patients
were asked to complete the EORTC QLQ-C30 questionnaire
before the start of treatment and thereafter every 6 weeks until
they went off the trial (Aaronson et al, 1993). Analyses were
restricted to changes at 12 and 18 weeks of global quality of life in
which physical function, pain, fatigue, and nausea/vomiting were
considered. Clinical significant changes required changes of X10%
points (Osoba et al, 1998).
Treatment-related adverse events
Toxicity was defined using the National Cancer Institute (NCI)
Common Toxicity Criteria, version 3.0 (National Cancer Institute,
Bethesda, MD, USA). The treatment was delayed at the first
occurrence of grade II haematological toxicity, and administered at
the same dose after it returned to grade I or better. In the case of
grade III or IV toxicity, the treatment was interrupted and a
maximum of 3 weeks were allowed for recovery, after which the
patients were withdrawn from the study. In the case of a second
episode of grade III or IV toxicity in the same patient, treatment
was resumed after recovery and the subsequent administrations of
each drug were reduced to 20mgm
 2. A prophylactic use of
haematopoietic growth factors was not applied. Chemotherapy was
discontinued, if the ejection fraction decreased below the
institutional lower limit of normal and declined by X15%.
Statistical analysis
The primary end point was the comparison of PFS between groups
in the per-protocol population. The PFS was calculated as the time
from the first chemotherapy infusion to disease progression or
death. Previous trials investigating the conventional D/P treatment
indicate that B60% of patients are progression free 6 months after
treatment onset. The hypothesis for the current study was that,
using the combined D/EPI schedule, at least 75% of patients would
be progression free after 6 months from the start of chemotherapy.
It was calculated that 32 evaluable patients per arm would have to
be recruited to yield a 90% probability to correctly select the best
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streatment when it is superior by absolute difference of 15% in
response rate (Simon et al, 1985). It was planned to enrol at least
70 patients in the expectation of 10–15% of unevaluable cases.
Patients were randomised by using a computer-generated random
list, and there were no stratification factors.
Secondary end points were safety, PSA response, duration of
response (RD), changes in bone markers, quality of life, and
overall survival (OS). The PFS, RD, and OS were determined
using the Kaplan–Meier method to provide the median value and
95% CI, and treatment groups were compared using the log-rank
test. Comparison of median percentage change from baseline of
bone markers during the observation period between the two
groups was analysed using the Mann–Whitney test. All tests were
two –sided, with a significance level of 0.05. Baseline clinical
characteristics, response rates, and adverse events were compared
using w
2 statistics. All data were analysed by MedCalc software
(MedCalc Statistical Software, Mariakerke, Belgium).
RESULTS
Patient characteristics
Between October 2005 to January 2010, 72 advanced CRPC patients
were enrolled in the study and randomly assigned to treatment: 37
to D/EPI and 35 to D/P. The recruitment period was 4.3 years, and
this enough extensive time was mainly because of the monocentric
characteristic of the study. The median age was 72 years (range
53–82 years) in the D/EPI arm and 70 years in the D/P arm (59–83
years). A total of 32 patients in the D/EPI arm and 29 patients in
the D/P arm had bone metastases: 12 patients in the D/EPI arm
and 13 patients in the D/P arm had measurable disease. Median
baseline serum PSA was 82ngml
 1 (range 14–182ngml
 1) in the
D/EPI arm and 66ngml
 1 (range 11–253ngml
 1) in the D/P arm
(Table 1).
Treatment
A total of 893 weekly cycles of D/EPI (median 25 cycles, range
1–30) and a total of 253 three-weekly cycles of D/P (median
7 cycles, range 3–10) were administered in the evaluable
per-protocol population.
Efficacy
The median duration of follow-up was 28.5 months (range
0.5–38.5 months): one patient in the D/EPI arm received only
one treatment cycle for chemotherapy-unrelated reasons and was
lost to follow-up; two patients in the D/EPI arm and one patient in
the D/P arm were lost to follow-up after the first 6 months. All
patients were included in the overall analysis (intent-to-treat).
The efficacy results are summarised in Table 2. After 6 months
from the onset of treatment, 83.7% of patients in the D/EPI
arm and 57.1% of patients in the D/P arm were free from
progression (P¼0.02). The PFS differed significantly between the
two treatment arms: median of 11.1 months (95% CI 9.2–12.6
months) in the D/EPI arm vs 7.7 months (95% CI 5.7–9.4 months)
in the D/P arm (P¼0.0002) (Figure 1).
A total of 32 patients (86.4%) in the D/EPI arm and 30 (85.7%)
in the D/P arm received a second-line chemotherapy: 23 patients in
the D/EPI arm (62.1%) and 16 patients in the D/P arm (45.7%)
were retreated with D after completion of first-line chemotherapy.
As salvage treatment, 24 patients in the D/EPI arm and 18 patients
in the D/P arm were enrolled in an ongoing trial with a treatment
consisting of weekly D and the anti-angiogenic agent bevacizumab
(Bev).
As of 31 August 2010, 21 patients in the D/EPI arm and 26
patients in the D/P arm had died: the median survival was 27.3
months (range 7.2–38.4 months; 95% CI 22.1–30.8 months) with
D/EPI vs 19.8 months (range 3.8–31.6 months; 95% CI 14.4–24.8
months) with D/P (P¼0.003) (Figure 2).
A confirmed 450% decrease in PSA was achieved in 28 patients
(75.6%; 95% CI 59.8–86.6%) in the D/EPI arm and in 19 patients
(54.2%; 95% CI 38.1–69.5%) in the D/P arm (P¼0.09). The PSA
levels decreased 475% in 22 patients in the D/EPI arm (PSA
returned o4ngml
 1 in 8 patients) and in 7 patients in the D/P
arm (PSA returned o4ngml
 1 in 3 patients). A total of 26 of the
28 PSA responses in the D/EPI arm and 14 of the 19 PSA responses
in the D/P arm were observed within the first 8 weeks of treatment.
Five patients (13.5%) in the D/EPI arm and 11 (31.4%) in the D/P
arm had stable PSA levels for at least 3 months. A partial response
on measurable disease was achieved in seven patients (58.3%) in
the D/EPI arm and in five patients (38.4%) in the D/P arm.
In subjects who were symptomatic at baseline, pain was reduced
in 24 patients (72.7%; 95% CI 55.6–84.9%) in the D/EPI arm and
Table 1 Main patient characteristics at baseline
D/EPI D/P
Enrolled patients 37 35
Median age (range), years 72 (51–82) 70 (56–83)
Initial Gleason score
p71 6 1 7
8–10 21 18
ECOG performance status
08 1 1
1–2 29 24
Sites of metastases
Bone 25 22
Bone + prostate cancer 5 6
Bone + lymph nodes 2 1
Lymph nodes + prostate cancer 3 5
Lymph nodes + liver 1 0
Prostate + lung 1 1
Median baseline serum PSA
(range), ngml
 1
82 (14–182) 66 (11–253)
Previous treatments
Prostatectomy 26 24
Radiotherapy 6 8
Hormone therapies
13 7 3 5
X22 2 1 8
Duration of response to hormonal treatment (months)
Median (range) 23 (6–52) 25 (7–68)
Baseline pain intensity
03 5
11 0 8
21 4 1 6
36 5
42 1
50 0
Median LDH, Ul
 1 (range) 278 (106–1,147) 233 (124–936)
Alkaline phosphatase, Ul
 1 (range) 131 (34–751) 147 (41–582)
Median haemoglobin, gdl
 1 (range) 11.8 (8.5–14.2) 10.9 (8.1–13.7)
Overall quality of life (EORTC)
a
Mean score±s.d. (range) 46 ± 9.57 (28–65) 42 ± 9.24 (33–59)
Abbreviations: D¼docetaxel; ECOG¼Eastern Cooperative Oncology Group;
EORTC¼European Organization for Research and Treatment of Cancer;
EPI¼epirubicin; LDH¼lactate dehydrogenase; P¼prednisone; PSA¼prostatic
specific antigen.
a0¼very poor; 100¼excellent.
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sin 13 (43.3%; 95% CI 27.3–60.9%) in the D/P arm (P¼0.02). The
median duration of palliative response was 10.6 months in the
D/EPI arm and 5.9 months in the D/P arm (P¼0.003).
Bone scan, which could be repeated after 6 months (range 6–8
months) in 31 patients in the D/EPI and in 27 patients in the
D/P arm, revealed two or more new lesions compared with scan at
trial entry in one patient in the D/EPI arm and in 4 patients the
in D/P arm.
Of 32 patients with bone metastases in the D/EPI arm, 25
(78.1%) and 21 (65.6%) had baseline s-CTX and B-ALP above the
normal range, respectively. Of 29 patients with bone metastases
in the D/P arm, 21 (72.4%) and 18 (62.0%) had baseline s-CTX
and B-ALP above the normal range, respectively. At 3 months
of treatment, the median s-CTX reduction was 71% (95% CI
58.3–71.4%) below baseline in the D/EPI group compared with
66% (95% CI 56.2–75.8%) in the D/P arm (P¼0.21). At 3 months,
both chemotherapy regimens similarly decreased the bone marker
B-ALP (D/EPI 62.4%; 95% CI 47.3–74.4% and D/P 59.1%; 95%
CI 42.8–71.7%).
Quality of life
Baseline QLQ-C30 data were available for 67 patients (34 D/EPI
and 33 D/P). Compliance with QL assessment decreased to 63
patients (87.5%) after 12 weeks and 56 (77.7%) after 18 weeks. At
12 and 18 weeks, global quality of life improved in 54.5 and 44.8%
of patients in the D/EPI arm, and in 30.0 and 23.3% of patients in
the D/P arm, respectively. There was a trend (Pp0.1) towards a
better improvement in physical function and pain subscales in the
D/EPI arm compared with the D/P arm: nonetheless, the difference
in these quality of life parameters between the two treatment
groups did not reach the statistical significance. At 12 and 18
weeks, global quality of life worsened in 6.0 and 13.3% of patients
in the D/EPI arm and in 9.6 and 16.0% of patients in the D/P arm,
respectively.
Toxicity
Both regimens were generally well tolerated, and no unexpected
toxic effects were observed (Table 3). The median received
cumulative dose of 710mgm
 2 (range 30–750mgm
 2) for D
and 630mgm
 2 (range 30–720mgm
 2) for EPI in the D/EPI arm,
and 560mgm
 2 (range 190–700mgm
 2) for 3-weekly D in the
D/P arm.
No grade 4 toxicity or congestive heart failure was observed, and
99% of the cycles in the D/EPI arm and 97% of the cycles in the
D/P arm were administered on an outpatient basis. The most
frequent side effects were neutropaenia, anaemia, thrombocyto-
paenia, and fatigue, which were grade I or II in most cases.
Grade III/IV neutropaenia occurred in 18.9% of patients in the
D/EPI arm and in 28.5% of patients in the D/P arm. The D/EPI was
associated with a trend for more grade 2–3 fatigue, nail changes,
and dry eye. Fatigue achieved grade 3 in three patients in the D/EPI
arm and in two patients in the D/P arm; the treatment was
resumed in all these patients after a 2-week interval.
The administration of at least one treatment cycle was delayed
by 1 week in 28 patients in the D/EPI arm and in 31 patients in the
D/P arm: the reasons for the delays were haematological in 24
(85.7%) and 28 cases (90.3%), respectively, and non-hematological
in 4 (14.3%) and 3 patients (9.7%), respectively. The dose of D and
Table 2 Responses to treatment
D/EPI D/P P-value
Enrolled patients 37 35
PSA response (%; 95% CI) 75.6 (59.8–86.6) 54.2 (38.1–69.5) 0.09
Median duration of PSA response (months; 95% CI) 12.4 (8.9–15.7) 7.5 (4.8–10.3) 0.0001
Median PFS (months; 95% CI ) 11.1 (9.2–12.6) 7.7 (5.7–9.4) 0.0002
Palliative response (%; 95% CI) 72.7 (55.6–84.9) 43.3 (27.3–60.9) 0.02
Median duration of palliative response (months; 95% CI) 10.6 (7.8–13.4) 5.9 (3.3–8.5) 0.003
Abbreviations: CI¼confidence interval; D¼docetaxel; EPI¼epirubicin; P¼prednisone; PFS¼progression-free survival.
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Figure 1 Estimated PFS for advanced CRPC patients randomly assigned
to D/EPI (—) or D/P (–––– )treatment.
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sEPI was reduced in 8 patients, and the dose of 3-weekly D in 12
patients. Two patients in the D/P arm definitely stopped the
treatment because of persistent severe neutropaenia after 6 and 7
three-weekly cycles, respectively. A decrease 415% in LVEF was
observed in three patients after, respectively, 24, 26, and 27 weekly
cycles in the D/EPI arm, and in one patient after 8 three-weekly
cycles in the D/P arm.
DISCUSSION
The results of this study suggest that the weekly D/EPI
combination is safe and achieves encouraging results over a
3-weekly D/P regimen in terms of PFS (median: 11.1 months vs 7.7
months) and survival (median: 27.3 months vs 19.8 months) in the
treatment of advanced CRPC. Moreover, although the utility of
a decrease 450% in PSA as a surrogate end point for PFS and
OS remains questionable (Collette et al, 2005); PSA response
was higher and time-to-response was shorter in the D/EPI arm
compared with that observed in the D/P arm. The efficacy results
we observed with the weekly D/EPI combination were consistent
with the best results that were reported with first-line chemother-
apy in advanced CRPC patients. A recent trial reported a 90% PSA
decline, 18.3 months of median PFS, and 28.2 months of median
OS with Bev combined with D, P, and thalidomide (Ning et al,
2010). However, the use of such a multiagent treatment may not be
suitable for most of CRPC patients who are elderly and with
various co-morbidities. The updated data of the phase III trial
CALGB 90401 reported interesting results in terms of PFS with
3-weekly D combined with Bev but no significant survival benefit
over D alone, whereas a greater morbidity and mortality was
associated to D/Bev (Kelly et al, 2010).
Although it was a monocentric study, our results seem both
clinically and statistically meaningful, as this study employed a
randomised design and few patients were lost to follow-up. The
numbers were small, and slight imbalances with respect to
the main baseline characteristics might represent a concern in
the current study (Table 1). However, the Halabi nomogram
suggested that patient populations were similar, with an estimated
median survival of about 17 months for the D/EPI arm and about
18 months for the D/P arm (Halabi et al, 2003).
An intriguing point is that the median PFS and also the median
survival (11.1 months and 27.3 months, respectively) in the D/EPI
arm were longer than the median PFS and survival (7.4 months
and 21.5 months, respectively) we observed in the phase II study
with the same the D/EPI regimen (Petrioli et al, 2007). In our
previous experience, we adopted a planned break after the first
12 weekly cycles of D/EPI in patients who responded or who had a
stable disease to minimise toxicity. Thus, it seems that in advanced
CRPC patients, the weekly D/EPI administered until the occur-
rence of progression may substantially prolong PFS compared
with a stop-and-go strategy. One might also speculate that the
continuative administration of D/EPI until progression can delay
the time-to-emergence of resistance disease compared with a stop-
and-go or an intermittent application of effective chemotherapy.
However, the small sample size of the studies and the absence of a
randomised comparison between different treatment strategies
prevent us from drawing definite conclusions in this setting.
Another point to consider in the survival analysis is that more
patients in the D/EPI arm could receive weekly D plus Bev as
salvage treatment (as third- or fourth-line chemotherapy), which
may offer a clinical benefit and an advantage in OS in heavily
pre-treated patients (our unpublished data; Heidenreich et al, 2010).
A rapid, high, and long-lasting pain response was observed in
the D/EPI arm after 6 weeks, with a superior statistical difference
compared with the D/P arm, and was probably related to the
potent rapid-onset activity of the D/EPI combination. The true
contribution of EPI, particularly in reducing bone pain in
symptomatic patients, has been reported by a recent review on
the use of anthracyclines in prostate cancer (Petrioli et al, 2008).
The efficacy results correlated well with changes in the bone
markers s-CTX and B-ALP in both the D/EPI and D/P arm at the
third month of treatment. These findings confirm the activity of
chemotherapy combined with bisphosphonates in reducing both
bone resorption and bone formation markers, and suggest the role
of early changes in bone markers for monitoring CRPC patients
with bone metastases (Francini et al, 2001; Brown et al, 2005;
Coleman et al, 2005).
The D/EPI arm showed a trend towards a superior improvement
in a number of quality of life dimensions compared with the D/P
arm, particularly pain and physical function subscales, and global
quality of life. Although the integration of a prostate cancer-
specific module would have been helpful, these results further
suggest the palliative effect achieved by the association of D
with an anthracycline in metastatic CRPC patients. It appears that
patients in the D/EPI arm received three doses of corticosteroids
Table 3 Number of patients experiencing the most frequent treatment-related adverse events
D/EPI D/P
Toxicity Grade 2 (%) Grade 3–4 (%) Grade 2(%) Grade 3–4 (%)
Haematological
Neutropaenia 16 (43.2) 7 (18.9) 17 (48.5) 10 (28.5)
Anaemia 13 (35.1) 5 (13.5) 12 (34.2) 3 (8.5)
Thrombocytopaenia 7 (18.9) 3 (8.1) 6 (17.1) 2 (5.7)
Non-haematological
Nausea/vomiting 6 (16.2) 3 (8.1) 12 (31.4) 9 (25.7)
Diarrhoea 4 (10.8) 1 (2.7) 5 (14.2) 1 (2.8)
Constipation 5 (13.5) 2 (5.4) 4 (11.4) 2 (5.7)
Nail changes 15 (40.5) 5 (13.5) 6 (17.9) 1 (2.8)
Dry eye/tearing 11 (29.7) 3 (8.1) 4 (11.4) 1 (2.8)
Myalgia/arthralgia 6 (16.2) 1 (2.7) 5 (14.2) 2 (5.7)
Fatigue 16 (43.2) 3 (8.1) 13 (37.1) 2 (5.7)
Sensory neuropathy 2 (5.4) 0 4 (11.4) 1 (2.8)
Peripheral oedema 3 (8.1) 1 (2.7) 7 (20.0) 2 (5.7)
Epistaxis 4 (10.8) 1 (2.7) 2 (5.7) 1 (2.8)
Dyspnoea 2 (5.4) 0 2 (5.7) 1 (2.8)
Abbreviations: D¼docetaxel; EPI¼epirubicin; P¼prednisone.
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severy week as pre-medication, whereas patients in the D/P
arm received them every 3 weeks. It is well established that
corticosteroids can improve quality of life in metastatic CRPC
patients (Tannock et al, 1996); however, it is unlikely that
differences in corticosteroids pre-medication regimen have had a
significant impact on the palliative outcomes in the D/EPI arm,
as patients in the D/P arm received also continuous oral P 5mg
twice daily.
Quality of life is strictly correlated with treatment tolerability,
and in this setting, the use of weekly EPI combined with weekly D
was not associated with a significant increase in toxicity compared
with 3-weekly D combined with P. Neutropaenia was, in the D/EPI
arm, only slightly more frequent than the rate usually observed
with EPI alone, whereas more grade 3/4 occurred in the D/P arm,
as reported with the conventional 3-weekly D (Table 3) (Tannock
et al, 2004). Other differences in most common adverse events
were mainly related to the different schedule of D administration
(i.e., weekly vs 3 weekly). Despite the use of an anthracycline, the
D/EPI arm was associated with a low incidence of cardiotoxicity.
As a matter of fact, the weekly EPI schedule was chosen because we
had previously demonstrated that this drug can be administered
weekly for long periods without giving rise to more than mild toxic
effects (Francini et al, 1993; Petrioli et al, 2002).
As expected, the characteristic and cumulative D toxicities of
fatigue, tearing, and nail disorders were mild and slightly more
frequent than those reported in our previous experience with
D/EPI, in which the stop-and-go strategy probably contributed to
minimise their occurrence (Petrioli et al, 2007). In conclusion,
treatment of advanced CRPC with weekly D combined with weekly
EPI was feasible and tolerable, and led to encouraging results in
terms of PFS over treatment with a 3-weekly D (70mgm
 2)
regimen combined with oral P. Although the improvement in PFS
may not reflect a significant improvement in OS, these results
suggest that the combination of D and EPI may warrant an
eventual expansion to a phase III trial on CRPC.
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